BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Araki Y, Yanagida M. Hypertensive disorders of pregnancy: Strategy to develop clinical peptide biomarkers for more accurate evaluation of the pathophysiological status of this syndrome. Adv Clin Chem 2020;94:1-30. [PMID: 31952570 DOI: 10.1016/bs.acc.2019.07.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Araki Y, Yoshitake H, Yamatoya K, Fujiwara H. An overview of sex and reproductive immunity from an evolutionary/anthropological perspective. Immunol Med 2020;:1-7. [PMID: 33043824 DOI: 10.1080/25785826.2020.1831219] [Reference Citation Analysis]
2 Araki Y, Miura Y, Fujiwara H. Exploration of novel biomarkers for hypertensive disorders of pregnancy by comprehensive analysis of peptide fragments in blood: their potential and technologies supporting quantification. Clin Chem Lab Med 2021. [PMID: 34664478 DOI: 10.1515/cclm-2021-0713] [Reference Citation Analysis]
3 Wakabayashi I, Yanagida M, Araki Y. Associations of cardiovascular risk with circulating peptides related to hypertensive disorders of pregnancy. Hypertens Res 2021;44:1641-51. [PMID: 34584228 DOI: 10.1038/s41440-021-00747-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 He X, Ding D. High miR-200a-3p expression has high diagnostic values for hypertensive disorders complicating pregnancy and predicts adverse pregnancy outcomes. BMC Pregnancy Childbirth 2022;22:490. [PMID: 35705894 DOI: 10.1186/s12884-022-04785-x] [Reference Citation Analysis]